Body Systems

Multiple Myeloma17 Results found

Studies recruiting participants:

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or…

This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone (LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myelom

Recruiting
Principal Investigator 
Kevin Song
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 and above

An Investigational Immuno-therapy Study of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602)

The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either:

Recruiting
Principal Investigator 
Kevin Song
Body Locations and Systems 
Blood, Heart and Circulation
Area 
Vancouver
Age 
18 years and above

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON

This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade® or generic equivalent) plus low-dose dexamethasone (SVd) versus bortezomi

Recruiting
Principal Investigator 
Heather J. Sutherland
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 years and above

Closed for recruitment:

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of pomalidomide monotherapy in subjects with refractory or relapsed and refractory multiple myeloma who were enrolled in study CC-4047-MM-003 (NCT01311687) and discontinued treatment with high-dose dexamethasone due to disease progr

Closed for Recruitment
Principal Investigator 
Kevin Song
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 and above

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.

Closed for Recruitment
Principal Investigator 
Heather J. Sutherland
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 and above

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients…

The purpose of this phase 3, randomized, double-blind, multicenter study is to compare Oral Ixazomib (MLN9708) plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in adult patients with relapsed and/or refractory multiple myeloma.

Closed for Recruitment
Principal Investigator 
Kevin Song
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 and above

A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly…

The purpose of the study is to compare once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent

Closed for Recruitment
Principal Investigator 
Kevin Song
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 and above

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and other hematologic malignancies that express B cell maturation antigen (BCMA).

Closed for Recruitment
Principal Investigator 
Heather J. Sutherland
Body Locations and Systems 
Blood
Area 
Vancouver
Age 
18 and above